Want to avoid a devastating drug shortage? Aric Meares, CEO of Azbil BioVigilant, says rapid microbial detection technology is a critical part of the solution…
Aric Meares, CEO, Azbil BioVigilant
Want to avoid a devastating drug shortage? Aric Meares, CEO of Azbil BioVigilant, says rapid microbial detection technology is a critical part of the solution.
With more than 20 years of experience in technical roles with technologies ranging from precision measurement equipment to advanced optical systems, Aric Meares joined BioVigilant in 2007 as its Vice President of Operations, and in 2011 became the President and CEO. Founded in 2002 in Tucson, Arizona, originally inventing its instantaneous microbial detection tech nology to detect weaponised bio-agents for the US military and Homeland Security, BioVigilant commercialised the technology for the pharmaceutical market in 2007. Today, the systems detect, instantaneously and in real time, particulate count, size and biological status.
Aric Meares, CEO, Azbil BioVigilant
Over the past year, critical drug shortages used to treat a host of life-threatening illnesses have been making headlines. Microbial contamination has been cited as a major contributor to the shortage, yet the prevailing practices to ensure the safety of drugs have been slow to change. “In most cases, quality assurance practices safeguarding the drug making environment continue to rely on periodic air sampling and a culturing method from a prior century,” Meares says. “It takes great vision and courage to drive such a fundamental change in your manufacturing processes, especially in a regulated environment. The driving force for such a change is often driven by quality, but they face natural resistance from their financial organisations who expect a short return on investment and their manufacturing teams who are focused on maintaining the continuity of the processes that allow them to meet quarterly production goals.”
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
In the long run, Meares believes the impact of adopting rapid methods would enable the industry to move to real-time release and improve the final production output. “As with any disruptive technology advancement, it drives paradigm shifts that force users to re-think some of the fundamental assumptions on which the current practices are based,” Meares notes. “For instance, the setting of alert and action limits is an area requiring thought leadership from industry. There is a lot of evidence that a significant number of bacteria are present in an environment that cannot be grown on a culture plate. So if you implement a rapid method that is better at detecting these ‘viable but not culturable’ bacteria, you need to rethink – then justify – your limits, both inside your company and outwardly to regulators.”
While FDA regulators seem to be open to changing limits, pharmaceutical companies remain cautious, facing practical issues related to establishing the amount of data that need to be collected, the statistical methodology to apply to it and trepidation that an inspector could prevent drugs from being released if a rapid method being evaluated generates higher counts than the current validated method. “The FDA has the ‘Research Exemption’, an internal memo recognised by the FDA, that allows a drug maker to collect evaluation data on an alternative rapid method while drugs are being made,” Meares explains. “The company is expected to continue to rely on the validated method in place and will not suffer any regulatory ramifications. BioVigilant offers its customers the support of our field applications scientists and statisticians to develop sound validation plans and methods that are suitable for their products and manufacturing environments.”
Ultimately, time to result is the key factor in microbial detection. “You can’t get much faster than instantaneous microbial detection and we invented it,” Meares says. “In addition, we are focused on helping our customers realise the benefits that result from instantaneous microbial detection, rather than serving up a method that may fit the current compendial requirements but doesn’t move the ball forward on quality assurance. When you consider the future of environmental monitoring, microbial monitoring is one of the last parameters not monitored continuously and in real time in the production environment. Process engineers have ready solutions in place to sense and control temperature, humidity, and pressure, but not bioburden.”
In May 2009, Yamatake Corporation of the azbil Group acquired the majority stock of BioVigilant, extending its expertise in auto – mation which includes a growing portfolio of products and solutions organised into Building Automation, Advanced Automation and Life Automation business units. As of this year, all affiliates now include Azbil in their names, and Yamatake itself became known as Azbil Corporation, on the 105th anniversary of the company’s founding in April. The core value that BioVigilant is striving to deliver is providing automation that, first and foremost, serves the needs of humanity and the pharmaceutical companies who share in that common goal.
I disagree with some of the information in this article regarding drug shortages. Most have nothing to do with rapid environmental air detection and everything to do with drug companies not following drug GMPs. They also tend to cut corners on Quality Systems. Not one FDA consent decree has been issued for a non-viable or viable air excursion. In fact, environmental monitoring is rarely even a topic in a consent decree. If mentioned, it is a subset of lack of microbiological control.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
I disagree with some of the information in this article regarding drug shortages. Most have nothing to do with rapid environmental air detection and everything to do with drug companies not following drug GMPs. They also tend to cut corners on Quality Systems. Not one FDA consent decree has been issued for a non-viable or viable air excursion. In fact, environmental monitoring is rarely even a topic in a consent decree. If mentioned, it is a subset of lack of microbiological control.